Capella RF, Iannace VA, Capella JF Bowel obstruction after open and laparoscopic gastric bypass surgery for morbid obesity. J Am Coll Surg. 2006 Sep;203(3):328-35. Epub 2006 Jul 27.
Felsher J, Brodsky J, Brody F Small bowel obstruction after laparoscopic Roux-en-Y gastric bypass. Surgery. 2003 Sep;134(3):501-5.
Filip JE, Mattar SG, Bowers SP, Smith CD Internal hernia formation after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Am Surg. 2002 Jul;68(7):640-3.
Flum DR, Khan TV, Dellinger EP Toward the rational and equitable use of bariatric surgery. JAMA. 2007 Sep 26;298(12):1442-4.
Gould JC, Garren MJ, Boll V, Starling JR Laparoscopic gastric bypass: risks vs. benefits up to two years following surgery in super-super obese patients. Surgery. 2006 Oct;140(4):524-9; discussion 529-31.
Higa KD, Boone KB, Ho T, Davies OG Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients. Arch Surg. 2000 Sep;135(9):1029-33; discussion 1033-4.
Higa KD, Ho T, Boone KB Internal hernias after laparoscopic Roux-en-Y gastric bypass: incidence, treatment and prevention. Obes Surg. 2003 Jun;13(3):350-4.
http://www asbs.org/htm/Private/resolution.html. American Society of Metabolic and Bariatric Surgeons.
Hwang RF, Swartz DE, Felix EL Causes of small bowel obstruction after laparoscopic gastric bypass. Surg Endosc. 2004 Nov;18(11):1631-5. Epub 2004 Oct 11.
Meguid MM, Glade MJ, Middleton FA Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008 Sep;24(9):832-42. doi: 10.1016/j.nut.2008.06.027. Review.
Nguyen NT Reoperations and revisions in bariatric surgery. Surg Endosc. 2007 Nov;21(11):1907-8. Epub 2007 Sep 8.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.